Now you know why GBIM trades at a $50M market cap and why I like it ahead of GILD data.
Why would $GILD start 2 new studies with the drug if the data from the open label study was looking bad? Plus, if they are indeed presenting at ISHVLD, would make no sense to present negative or data from a drug they intend to dump.
The HBV trial ended after the deadline for abstracts for EASL were due, thus GILD will not be able to present the data at EASL. They can PR it around EASL or concurrently with their Q1 earnings in a few weeks. Or there are some other conferences in Q2.
The stock is down because apparently there were unrealistic expectations for news to come out today.
Another way to look at it is: the fact that they are not raising ahead of major data is only a good thing. Implies where they think the stock is going.
That was another poster who made that comment. So you are telling me with only 5.7M shares outstanding that if GBIM can produce strong HBV data (better than ARWR, etc) this can't skyrocket to the moon? ARWR has a $400M market cap! GBIM is currently at $47M. At $30 GBIM is only worth $180M.
TRVN burns 5-6x more cash per qtr than GBIM who only burns $2m. Plus Gilead and Celgene are paying the cost of the trials. They dont have a need for cash now. If stock is $20-30 in 2 months after data it makes sense to raise then.
You think the stock would be trading in single digits if the assets were worth billions in this market climate?
May have never been a viable asset to begin with. So some think.